Leniolisib (CDZ173) Synthesis and Patent Landscape
The synthesis of leniolisib (CDZ173) involves complex chemical processes, and its patent protection is crucial for its commercialization. The drug, developed by Novelmed, is a selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor [1].
What is Leniolisib Used For?
Leniolisib, marketed as Joenja, is approved for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency [2]. APDS is characterized by a variety of symptoms including recurrent respiratory tract infections, autoimmunity, and lymphoproliferation [3].
How is Leniolisib Synthesized?
While specific detailed synthesis routes are often proprietary, the development of small molecule drugs like leniolisib typically involves multi-step organic synthesis. This requires careful control of reaction conditions, purification of intermediates, and characterization of the final active pharmaceutical ingredient (API) [4]. The patent literature often provides general synthetic schemes or key intermediate preparations, but precise industrial-scale manufacturing processes are usually trade secrets.
When Does Leniolisib's Patent Protection Expire?
Patent expiry dates are critical for understanding when generic versions of a drug might become available. Information on the specific patent expiry for leniolisib can be found through specialized patent databases [5]. These databases track the filing and expiration of patents related to drug substances, formulations, and methods of use.
Who Else is Developing PI3Kδ Inhibitors?
The PI3Kδ pathway is a target for various therapeutic indications, and several other companies are developing PI3Kδ inhibitors. These may be for similar immunodeficiencies or other conditions such as certain types of cancer and autoimmune diseases [6]. For example, drug candidates from companies like Gilead Sciences and others have been explored for different applications [7].
What Are the Potential Risks with Leniolisib?
As with any medication, leniolisib carries potential risks and side effects. The most common side effects reported in clinical trials include headache, nausea, and diarrhea [2]. Healthcare providers monitor patients for adverse events during treatment.
How Does Leniolisib Differ from Other Immunodeficiency Treatments?
Leniolisib's mechanism of action as a selective PI3Kδ inhibitor differentiates it from other treatments for primary immunodeficiencies. While treatments like immunoglobulin replacement therapy manage symptoms by providing antibodies, leniolisib targets the underlying molecular defect in APDS by inhibiting the hyperactive PI3Kδ pathway [3].
Sources:
[1] Novelmed Therapeutics. (n.d.). Leniolisib. Retrieved from https://www.novelmed.com/leniolisib
[2] U.S. Food & Drug Administration. (2023). FDA approves Joenja (leniolisib) oral𝗋 tablets for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS). Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-joenja-leniolisib-oral-tablets-treatment-activated-phosphoinositide-3-kinase-delta
[3] Imai, K., et al. (2018). An autosomal dominant gain-of-function mutation in PIK3CD causes activated phosphoinositide 3-kinase δ syndrome. The Journal of Allergy and Clinical Immunology, 142(3), 910-919.e7.
[4] Comprehensive Drug Development Services. (n.d.). API Synthesis. Retrieved from https://www.drugdevelopment.com/services/api-synthesis/
[5] DrugPatentWatch.com. (n.d.). Leniolisib Patents. Retrieved from https://drugpatentwatch.com/drugs/leniolisib
[6] De Smedt, L., et al. (2021). PI3Kδ Inhibitors in Clinical Development. Cancers, 13(24), 6418.
[7] Gilead Sciences. (n.d.). PI3K Delta Inhibitors. Retrieved from https://www.gilead.com/science-and-medicine/research-and-discovery/pipeline/pieris